More Algorae Pharmaceuticals Limited news
Algorae Pharmaceuticals LimitedASX: 1AI

LCT JV secures funds to realise the potential of DIABECELL

Mar 30, 2016 at 7:43 AM EDT · Issued by Algorae Pharmaceuticals Limited

Filed with ASX · Mar 30, 2016 at 7:43 AM EDT · 2 pages · English

On 6ix: 6ix.com/news/lct-jv-secures-funds-to-realise-the-potential-of-diabecell

Algorae Pharmaceuticals Limited on 6ix

Earlier from Algorae Pharmaceuticals

  • LCT starts Phase IIb clinical trial of NTCELLMar 23, 2016
  • LCT completes $2.8m private placement and announces SPPFeb 16, 2016
  • LCT receives ethics approval for Phase IIb Parkinsons trialFeb 11, 2016
  • NTCELL reverses the progression of Parkinsons diseaseFeb 10, 2016

Later from Algorae Pharmaceuticals

  • NTCELL demonstrates continued reversal of ParkinsonsJun 7, 2016
  • LCTs joint venture focuses on US developmentsAug 22, 2016
  • Group 1 patients successfully treated in Parkinsons trialOct 4, 2016
  • Appendix 4C Quarterly Cash Flow Report 30 September 2016Oct 19, 2016
  • Approval granted for group 2 in Parkinsons trialNov 10, 2016
All Algorae Pharmaceuticals news releases↗

Follow Algorae Pharmaceuticals into a list and get an email when it puts out news.

Follow Algorae Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer